Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Transdermal Ltd.
Lost In The Middle: Why Value Added Products Need Better Pricing Mechanisms
Europe needs better pricing systems for so-called value added medicines if the market for such products is to be sustainable or attractive, Warrick Smith, director general of the British Generic Manufacturers Association, the BGMA, told Scrip.
Corium names business chief
Menlo Park, California-based Corium, a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, has appointed Dr Joseph J Sarret to the newly created position of chief business officer. Reporting to Corium's president and CEO Peter D Staple, Dr Sarret will serve as a member of the company's executive leadership team with responsibility for developing and implementing Corium's business strategies, building new alliances and expanding existing ones, and pursuing new business initiatives that leverage Corium's advanced transdermal technologies and product candidates.
New EU guideline on development of modified-release formulations
The European Medicines Agency has agreed a new guideline on the development of modified-release dosage forms, describing the studies that will be needed to demonstrate the efficacy, safety and pharmacokinetic properties of formulations such as prolonged, delayed and multiphasic-release formulations of medicines.
FDA rejects Actavis norethindrone contraceptive patch
There were no good wishes to Actavis this week from the FDA, which doled out a Christmas Eve complete response letter (CRL) to the company on its progestin-only contraceptive patch, known as the Norethindrone Transdermal Delivery System.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice